15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

Also called NCT02021370

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02021370
  • EudraCT 2013-001193-14
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Bulgaria, France, Germany, Hungary, Israel, Italy, Japan, Poland, Romania, South Korea, Spain, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02021370. Randomized; quadruple masking; primary purpose treatment. Start 2014-02-10 (actual); primary completion 2015-09-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)
Acronym
DIALOGUE 1
Condition
Anemia
Condition
Renal Insufficiency, Chronic
Intervention (Drug)
BAY85-3934
Intervention (Drug)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02021370
Content hash
71ce0a30521d4de9bf9ade8f5bd2b2065fb6c62fda5316661622c1aad7d93285